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histopathological and molecular stages in colorectal cancer 
(CRC). CRCs develop from apparently normal mucosa 
into a benign precursor stage, the premalignant polyp, 
and can progress to invasive disease[1]. The molecular 
mechanisms driving this process and the important 
pathological landmarks that characterize CRC, however, 
are being continually refined. 
In 1988, Vogelstein et al published their molecular 
analysis of  172 colorectal neoplasias, including adenomas 
from patients with familial adenomatous polyposis (FAP), 
sporadic adenomas, and CRCs[2]. They characterized 
several of  the sentinel molecular events occurring in 
progressive pathological stages, from adenoma to cancer. 
This research generated the ‘traditional pathway’ model 
that integrated these events into a coherent adenoma-
carcinoma sequence[3]. Conceptually, this traditional 
model of  the adenoma-carcinoma sequence is extremely 
attractive. It is relatively uncomplicated, it is likely to 
explain the growth of  many cancers and, within the 
context of  CRC screening, supports the clinical practice 
of  removing adenomas to reduce, albeit very slightly, the 
incidence of  invasive neoplasia[4]. The natural history of  
adenomas, hyperplastic polyps, and carcinomas, however, 
is extremely variable. The discovery of  one such subset of  
phenotypically distinct CRC, the microsatellite instability-
high (MSI-H) group, represents another key milestone 
in the scientific history of  CRC[5]. MSI-H CRCs show 
particular histopathological characteristics, a proclivity 
for the proximal colon, relatively rapid progression from 
adenoma to invasive cancer, and generally have a better 
prognosis for a given stage of  disease[6]. MSI-H cancers 
result from failure of  the mismatch repair (MMR) system, 
which is critical in maintaining genetic fidelity following 
DNA replication[7]. MMR dysfunction may be caused by 
germline mutation of  MMR genes as in Lynch syndrome, 
also known as hereditary non-polyposis CRC (HNPCC) 
or somatic (epigenetic) inactivation of  an MMR gene, 
most commonly MLH1 [8]. There are other colorectal 
lesions, however, that do not strictly conform to either of  
these pathways. Some cancers exhibit unique pathological 
features and distinct molecular signatures that translate 
into specific natural histories. The discovery of  epigenetic 
mechanisms in colorectal carcinogenesis has necessitated 
the development of  new frameworks and pathways[9]. 
More precise characterization of  colorectal carcinogenesis 
and a better appreciation of  the interplay between genetic 
predisposition, environmental exposure and luminal events, 
will generate new opportunities to improve screening, 
surveillance, chemoprevention and therapeutic strategies.
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Abstract
This review explores the chief genetic and epigenetic 
events that promote pathological progression in colorectal 
carcinogenesis. This article discusses the molecular and 
pathological basis for classifying colorectal neoplasia 
into suppressor, mutator and methylator pathways. 
These differing mechanisms of genomic instability are 
associated with specific cancer characteristics, and may 
provide the opportunity for more effective prevention 
and surveillance strategies in the future. This is the first 
review in a series of five topics outlining important and 
developing aspects of colorectal cancer.
© 2007 WJG. All rights reserved.
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INTRODUCTION
Rapid integration of  new endoscopic and molecular 
techniques into clinical practice, has established colorectal 
medicine in the vanguard of  translational research. Close 
collaboration between surgeons, gastroenterologists, 
oncologists, pathologists, geneticists and molecular 
scientists has advanced our understanding of  the 
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This article reviews recent developments in defining 
colorectal cancer pathways. In particular, we identify 
the chief  genetic events that advance neoplasia, outline 
the histopathological correlates of  these molecular 
perturbations and, where possible, contrast these differing 
mechanisms to emphasize the clinical value of  dissecting 
out these road maps to cancer. 
CaNCeR: a DIsTURbaNCe Of mUTaTION, 
RepaIR aND expRessION
Colorectal carcinogenesis requires a previously normal cell 
to accumulate multiple genetic alterations and establish 
successive clones, each characterized by relative growth 
advantage. This growth advantage may be conferred 
through an increased rate of  proliferation, impaired 
apoptosis, or both. Most cancers probably require between 
6 to 10 clonal events to reach their final malignant 
phenotype, which also requires the acquisition of  
metastatic traits[10]. In addition to simple growth advantage, 
the “successful” pre-cancerous clone must develop a 
cellular environment permissive of  future mutation[7]. This 
process, referred to as genomic instability, ensures that 
subsequent strategic mutations occur at increasingly greater 
likelihood. Genomic instability is critical in carcinogenesis. 
It accelerates the neoplastic evolutionary process, by 
increasing the mutation rate induced by the background 
mutagenic challenge. Without genomic instability, the 
acquisition of  new mutations would occur far too slowly 
for a cancer to develop during a person’s lifetime[11]. 
Genomic integrity in a normal cell is under careful 
scrutiny. The cell cycle and mitotic spindle checkpoints are 
critical in this process to ensure that cell proliferation only 
follows correct replication and organization of  genetic 
material, respectively. If  the genetic damage is too great 
for repair, the cell avoids propagating the damaged DNA 
by undergoing apoptosis. When one particular type of  
genomic instability predominates and neoplasias progress 
through characteristic histopathological stages with similar 
genetic alterations, then it is appropriate to consider such a 
process as a discrete pathway.
There are two chief  categories of  genomic instability 
in colorectal cancer. The most common is chromosomal 
instability (CIN), in which the requisite genetic events 
occur through the accumulation of  numerical or structural 
chromosomal abnormalities (aneuploidy)[10]. The other 
main type of  genomic instability is microsatellite instability 
(MSI), which is a consequence of  impaired recognition 
and repair of  mismatched bases in the daughter strand 
of  DNA during DNA replication. Microsatellites are 
nucleotide repeat sequences scattered throughout the 
genome and MSI refers to discrepancies in the number 
of  nucleotide repeats found within these microsatellite 
regions in tumour versus germline DNA (see below). MSI 
testing reveals the mismatch repair dysfunction, which 
is responsible for generating the genetic events involved 
in the MSI pathway of  CRC. The mutual exclusivity of  
the pathways associated with CIN or MSI suggests that 
genomic instability is necessary and that either pathway is 
sufficient to drive colorectal carcinogenesis. More recently, 
epigenetic factors have been implicated in the development 
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of  certain subsets of  cancers and polyps[9]. Careful 
characterization of  the epigenetics, particularly promoter 
sequence methylation, has led to the definition of  the 
CpG Island Methylator Phenotype (CIMP+) cancer and a 
proposed novel pathway, the serrated neoplasia pathway[12]. 
ChROmOsOmal INsTabIlITy paThway 
(CIN) OR sUppRessOR paThway 
Approximately 70%-85% of  CRCs generally develop via 
the ‘traditional’ pathway, which has also been referred 
to as the CIN, or ‘suppressor’, pathway[13]. The earliest 
identifiable lesion in this pathway is probably the dysplastic 
aberrant crypt focus (ACF), a microscopic mucosal lesion, 
that precedes the development of  a macroscopic polyp[14]. 
The ‘traditional’ pathway is associated with mutation in 
APC or loss of  5q (APC gene), mutation of  K-ras, loss 
of  18q, and finally, deletion of  17p, which contains the 
important tumour suppressor gene p53 (Figure 1)[13]. 
However, only a very small minority of  CRCs characterized 
by CIN possess a full complement of  these molecular 
abnormalities[15]. It is possible that several of  these “steps” 
can be bypassed by other genetic events to deliver the 
necessary biological consequences[16]. Sequencing of  the 
human genome has provided the opportunity to analyze 
tumour-specific mutations in far greater detail and a 
recent study discovered many potentially important CRC 
mutations outside of  the genes referred to above[17]. Some 
of  these mutations may serve as additional or alternative 
steps in the adenoma-carcinoma sequence. Nevertheless, it 
is still worthwhile to consider the traditional CIN pathway 
genes, as well as the Wnt-signaling pathway affected by 
APC dysfunction, in more detail.
APC (5q21) 
The adenomatous polyposis coli (APC) gene is large, containing 
15 exons with several functional domains, and is thus a 
prime target for mutagenesis. Pathogenic mutations in 
APC frequently truncate the APC protein, which in turn 
interferes with its binding to β-catenin. APC binding to 
β-catenin is an important step in dampening down the 
Wnt-signaling pathway[18]. Wnt signaling normally helps 
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Figure 1  Sporadic traditional/CIN/suppressor pathway: sequential pathological 
stages and molecular events.
to regulate growth, apoptosis and differentiation and 
thus is particularly relevant in embryogenesis, as well 
as maintaining tissue specific stem cell compartments, 
including the stem cell compartment found at the base 
of  colonic crypts[19]. Corruption of  this pathway can 
contribute to carcinogenesis in adulthood, with FAP 
providing a dramatic example. Normal activation of  the 
Wnt-pathway requires binding of  Wnt proteins, possibly 
secreted by neighbouring subepithelial cells[20], to the cell 
surface receptor complex of  the Frizzled receptor and the 
LDL-receptor-related protein (LRP) co-receptor. Binding 
to the receptor complex induces LRP-axin interaction 
as well as phosphorylation of  Disheveled, another 
cytoplasmic protein. Activated Disheveled interferes with 
the usual APC-axin-GSK3β-induced degradation of  
cytoplasmic β-catenin, which is then available to associate 
with Tcf, translocate to the nucleus as a transcription 
factor, and promote the expression of  several important 
cell cycle regulating genes, including cyclin D1 and c-Myc. 
Thus APC mutations that interfere with APC-β-catenin 
binding impair the normal degradation of  β-catenin and 
result in a constitutively active Wnt-signaling pathway. 
Occasionally β-catenin mutation, which renders the protein 
resistant to APC-degradation, can act as an alternative 
to APC mutation, emphasizing the importance of  Wnt-
signaling in CRC[20]. 
Loss of  functional APC might also interfere with the 
normal regulation of  mitosis, contributing to CIN[21]. 
During metaphase there is careful organization of  the 
sister chromatids to ensure their successful distribution to 
the daughter cells. Several cellular components, including 
the kinetochore, carefully coordinate this organization 
of  the chromatin, to ensure correct delivery during cell 
division. APC is a kinetochore-bound microtubule-
associated protein, and along with EB1, is important in 
promoting correct chromosomal alignment and subsequent 
chromosomal segregation[22]. APC deficient cells do not 
adequately detect chromosomal abnormalities during 
metaphase, yet can still proceed into anaphase (separation 
stage of  mitosis) potentially generating CIN[23]. There is 
some suggestion that the contribution of  APC to CIN 
may be related to the site of  somatic APC mutation[24]. 
Through this mechanism, impairment of  APC might be 
important in the loss of  other strategic loci[23]. 
In patients with FAP, all of  their cells harbour a 
germline mutation in one APC allele. Initiation of  the 
adenoma-carcinoma sequence in these patients follows 
subsequent inactivation of  the remaining normal copy of  
APC, often by deletion but occasionally through somatic 
mutation. Thus, the function of  the APC protein is altered 
in all FAP-associated ACF. In addition, K-ras mutation 
is seldom found in this familial form of  dysplastic ACF, 
whereas 82% of  nondysplastic and 63% of  dysplastic 
sporadic ACF have K-ras mutation and APC mutation is 
notably absent[14,25]. β-catenin immunofluorescence studies 
suggest that Wnt-activation occurs in FAP-related, but 
not in sporadic ACF. These findings support the concept 
that APC and the Wnt-pathway is less important in the 
earliest stages of  sporadic CRC development via the 
traditional pathway[14]. The frequency of  APC or β-catenin 
mutation in early adenomas has been reported as high as 
80%[14], although the rate of  APC mutation is significantly 
lower in some other series and often depends on the 
histopathological type of  adenoma[9]. Mutation of  APC 
is found in approximately 60% of  cancers arising from 
the colon and 82% of  rectal cancers[9]. Abnormalities in 
APC and the Wnt-pathway may represent a convenient 
mechanism to advance sporadic ACF into early adenomas 
or as a means of  advancing very early lesions into 
more advanced stages. The fact that abnormalities in 
APC are not universal in adenomas or even in cancers, 
however, indicates that other genetic alterations may 
serve as molecular surrogates, either within the traditional 
pathway, or through other mechanisms of  colorectal 
carcinogenesis[26,27]. 
K-ras (12p12) 
The K-ras proto-oncogene encodes a GTP-binding protein 
and when mutated can cause a loss of  inherent GTPase 
activity. Thus, hydrolysis of  active GTP into inactive GDP 
is impaired, causing constitutive signaling through the 
downstream pathway[28]. Activating K-ras mutations are 
found in 35%-42% of  colorectal cancers, and in a similar 
number of  advanced adenomas, but is less common in 
small adenomas[28]. This is despite the fact that K-ras 
mutations are frequent in sporadic dysplastic ACF (63%), 
suggesting that although K-ras mutation confers a growth 
advantage to its daughter cells, it is neither sufficient nor 
necessary to drive carcinogenesis[25]. The role of  K-ras is 
not unique to the traditional pathway and K-ras mutations 
are present in both adenomas and hyperplastic polyps, 
whilst APC mutation occurs specifically in adenomas[29]. As 
discussed below, K-ras has a developing role in the serrated 
neoplasia pathway.
SMAD2, SMAD4 and DCC
DCC, SMAD2 and SMAD4 are all located at 18q21.1, 
and allelic loss at this site is found in up to 60% of  
CRCs[2]. SMAD2 and SMAD4 are involved in the TGF-β 
signaling pathway, important in regulating growth as well 
as apoptosis. DCC encodes a transmembrane receptor that 
promotes apoptosis, in the absence of  its ligand, netrin-1. 
Historically, DCC has been implicated as the key driver of  
carcinogenesis from this cluster. In contrast to SMAD4, 
however, mutations in DCC and SMAD2 are rare in 
CRC, thus SMAD4 may be more influential in colorectal 
carcinogenesis[30]. Furthermore, germline mutation of  
SMAD4 can cause juvenile polyposis syndrome, which is 
associated with CRC[31]. 
p53 (17p13)
Loss of  p53, usually through allelic loss of  17p, is often 
a late event in the traditional pathway, and heralds 
the transition from pre-invasive to invasive disease. 
Several studies have shown that the frequency of  p53 
abnormalities, either mutation or loss of  heterozygosity 
(LOH), increases relative to the histological stage of  
the lesion within the pathway. Thus, abnormalities are 
found in 4%-26% of  adenomas, 50% of  adenomas with 
invasive foci, and in 50%-75% of  CRCs[28]. The functional 
p53 protein, which is stabilized by DNA damage, is an 
important transcription factor. It acts to increase the 
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expression of  cell-cycle retarding genes, to slow the cell 
cycle and provide sufficient time for DNA repair during 
occasions of  genetic insult. When genetic damage is too 
great for the cell to repair, p53 induces pro-apoptotic 
genes[32]. 
To summarize the events above, a widely accepted 
interpretation of  the sporadic CIN pathway would follow 
that the initial lesion is the dysplastic ACF, which often 
contains K-ras mutation. Acquisition of  an APC mutation, 
or loss of  5q, then contributes to the growth of  the ACF 
into an adenoma. It is unclear why the frequency of  K-ras 
mutation in non-advanced (< 1 cm, tubular) adenomas is 
relatively low (12%-30%), despite being reported in 63% 
of  dysplastic ACF[14]. It could be that APC mutations 
occur more readily in cells that are wild type for K-ras, so 
most APC wild type/K-ras mutant ACF are destined not 
to progress. It is possible that the APC wild type/K-ras 
mutant ACF lesions are diverted from the traditional 
pathway into other pathological streams. Or that the APC 
mutant/K-ras mutant lesions, when they develop, endow 
their respective clone with significant advantage, so that 
they pass more quickly into advanced pathologies, such as 
tubulovillous adenomas. This would cause an artefactual 
under-representation of  K-ras mutation in earlier adenoma 
stages. From this last hypothesis, it would follow that 
although APC is the gateway or shortcut to adenoma 
development, K-ras is a molecular shortcut to developing 
advanced adenomas, a prelude to cancer. The frequency 
of  K-ras and APC abnormality then remains relatively 
stable for the rest of  the pathway. LOH at 18q and loss of  
function of  DCC, SMAD2 and perhaps most importantly 
SMAD4, may further advance the pathway by interfering 
with apoptosis, allowing accumulation of  mutations that 
had hitherto induced cell-cycle arrest or programmed cell 
death. Finally, acquisition of  p53 mutation or functionally 
equivalent LOH at 17p accompanies the transition of  the 
benign lesion into invasive disease (Figure 1).
There is increasing evidence that the mitotic spindle 
checkpoint is an important factor in CIN[10]. This 
checkpoint serves to ensure that all the chromosomes 
are correctly aligned in metaphase, before advancing 
into anaphase. A partially compromised checkpoint 
provides the cell with a relative growth advantage. The 
mitotic-spindle-checkpoint genes hBUB1 and hBUBR1 
are occasionally mutated in colorectal cancer[33]. Loss of  
entire chromosomes may accompany overexpression of  
particular genes that affect the number of  centrosomes 
within the dividing cell[34]. For instance, overexpression of  
either STK15 kinase or POLO-like kinase (PLK1) can cause 
aneuploidy in cell lines[35,36]. The G1/S checkpoint genes 
p53, pRb, p16INK4A[37] and p21Waf1/Cip1[38], are also important in 
preventing aneuploidy, and abnormalities of  these genes 
have all been implicated in CRC. However, a thorough 
explanation of  the mechanisms behind CIN awaits further 
study.
The traditional model of  the adenoma-carcinoma 
sequence has provided a foundation for molecular 
classification of  colorectal carcinogenesis and has 
established a reference against which one may contrast 
other CRC molecular profiles. The shortcomings of  
the traditional model include a failure to explain why 
the majority of  benign adenomas never transform into 
invasive cancers. One study suggested that in large polyps 
(> 1 cm) the cumulative risk of  cancer was only 2.5%, 
8% and 24% at 5, 10 and 20 years, respectively[39]. From 
an autopsy series, the prevalence of  asymptomatic polyps 
in those greater than 75 years was 40%-60%, whilst the 
prevalence of  CRC was approximately 3%[40]. Thus in 
approximately 19 of  every 20 cases[41], the sequence would 
be better described as an adenoma-adenoma pathway. 
This probably reflects bottlenecks in carcinogenesis that 
chance and genomic instability are only occasionally able 
to overcome. In contrast the cancer risk is much higher in 
polyps originating in patients with HNPCC[42], and some 
histopathological groups from other pathways are similarly 
associated with a greater risk for cancer development[43]. It 
is uncertain whether advanced adenomas, characterized by 
high-grade dysplasia, villous architecture and size (≥ 1 cm) 
simply represent more advanced stages within the sequential 
advancement of  colorectal neoplasia, or whether these 
advanced changes are predetermined. Are there multiple 
tracks to take within this pathway, even though CIN is 
the key mechanism driving genomic instability? There are 
several possibilities for the heterogeneous natural history 
of  these adenomas, including luminal factors and the 
resultant environmental mutational load that is fuelling 
the genetic aberration. The variability might also relate to 
other modifying genetic, microbiological or immunological 
factors that temper progression through the sequence. 
Finally, the traditional pathway does not explain the 
contribution of  non-dysplastic precursor lesions, such as 
hyperplastic polyps, to CRC.
mICROsaTellITe INsTabIlITy (msI) OR 
mUTaTOR paThway
The MSI or mutator pathway is the other chief  mechanism 
for genomic instability in CRC. Approximately 20% 
of  CRCs display this “mutator” phenotype, in which 
failure of  the mismatch repair system interrupts normal 
review and repair of  DNA fol lowing repl icat ion. 
The MMR system is composed of  at least 7 proteins, 
hMLH1, hMLH3, hMSH2, hMSH3, hMSH6, hPMS1 
and hPMS2, which associate with specific partners to 
form functional heterodimers[7]. hMLH1 and hMSH2 
are essential components of  the human mismatch repair 
machinery and form five functional heterodimeric 
proteins (hMSH2-hMSH3; hMSH2-hMSH6; hMLH1-
hPMS1; hMLH1-hPMS2; hMLH1-hMLH3). DNA 
polymerase is susceptible to making errors in short repeat 
sequences, thus MMR dysfunction, which fails to repair 
these, results in detectable differences between tumour 
and germline DNA in the number of  copies found in 
these repeat sequences (microsatellites). Many colon 
cancers, however, have frameshift mutations at a small 
number of  microsatellites, thus a standardized panel 
of  microsatellites was devised to provide uniformity of  
definition for research and clinicopathological practice[44]. 
The panel includes two mononucleotide (BAT25 and 
BAT26) and three dinucleotide microsatellites (D5S346, 
D2S123, and D17S250). MSI-H is defined as MSI at ≥ 
2 (40%) of  the five specified sites, MSI-L (low) MSI at 1 
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site, and microsatellite stable (MSS) when no instability is 
demonstrated. MSI leads to a dramatic increase in genetic 
errors and several microsatellites are present in genes 
implicated in colorectal carcinogenesis, such as TGF-
βRII, Bax, Caspase 5, MSH3, MSH6, β-catenin, APC, IGF-
II, and E2F4[1]. MSI-H cancers are invariably diploid, as 
MMR dysfunction provides the mechanism of  genomic 
instability without the need for CIN, which characterizes 
the traditional pathway.
MSI-H tumours occur in HNPCC (Lynch syndrome), 
in which germline mutation in a particular MMR gene 
provides each cell with only one functional copy of  
the protein. Following a second somatic hit, the cell is 
rendered deficient in the specific MMR protein product, 
and thus incapable of  accurate mismatch repair. MSI is 
one possible pathological screening test, to help direct 
genetic testing for HNPCC. The majority of  MSI-H CRCs, 
however, are sporadic, the consequence of  epigenetic 
silencing of  MLH1[45]. Most, but not all, MSI-H tumours, 
whether sporadic or inherited, share similar biology, as 
characterized in Table 1. hMSH2 and hMLH1 are the two 
most frequently affected genes in HNPCC, whilst hMLH1 
is targeted for epigenetic silencing in sporadic MSI-H 
CRCs.
What of  the MSI-L cancers that display only a mild 
mutator phenotype? In HNPCC, germline mutations of  
MLH1 or MSH2 cause MSI-H cancers, whilst MSI-L 
lesions may be associated with MS H6 mutations[46]. 
Clinicopathologically, MSI-L cancers are similar to MSS 
tumours, but have a higher prevalence of  K-ras mutation 
(54% vs 27%) and a lower frequency of  5q LOH (23% 
vs 48%), whilst sharing MSS cancers’ reliance on APC[47]. 
Interestingly, the rate of  K-ras mutation in MSI-L cancers 
is higher than in either MSS or MSI-H (7%), rather than 
at an intermediate level, expected if  MSI-L were merely 
an interface between these other two pathways. The 
DNA repair gene MGMT removes mutagenic adducts 
from guanine, and inactivation of  MGMT is associated 
with a particular G to A transversion in K-ras. Given 
the association with K-ras, methylation of  MGMT was 
evaluated in sporadic CRCs stratified for MSI status. 
Methylation of  the MGMT promoter was significantly 
associated with MSI-L (64%), compared to either MSS 
(26%) or MSI-H (13%) tumours (P = 0.0001)[48]. It 
is possible that epigenetic silencing of  MGMT could 
overwhelm the reparative capacity of  the MMR apparatus, 
causing MSI-L cancers. Thus, epigenetic silencing of  
MGMT expression provides a potentially unifying 
mechanism for both the K-ras mutations and the low level 
of  MSI found in this group. These findings support the 
hypothesis that MSI-L tumours may constitute a unique 
molecular pathway. 
To investigate whether the adenoma is the precursor 
lesion in the mutator, as it is in the traditional pathway, 
MSI testing was performed on several different sporadic 
polyps, including tubular adenomas, hyperplastic polyps, 
serrated adenomas and mixed polyps (adjacent, yet discrete 
hyperplastic and adenomatous components). The MSI-L 
phenotype was demonstrated in a high proportion of  
hyperplastic polyps, serrated adenomas and mixed polyps, 
29%, 53% and 83%, respectively, but only in 13% of  
tubular adenomas[49]. It is postulated that hyperplastic 
polyps and other serrated lesions may act as histologically 
distinct precursors to the sporadic mutator pathway 
cancers[9]. In HNPCC, however, the precursor lesion is 
still likely to be the adenoma. MSI is often, albeit not 
universally, found in adenomas identified in patients with 
HNPCC[50]. In one study the rate of  MSI-H was 89% 
in adenomas found within 5 cm of  a cancer, and 77% 
of  those located > 5 cm from cancer[50]. MSI, of  at least 
one marker, can occasionally be found in ACF[51], and 
MSI-L ACF are associated with methylation of  MGMT[51]. 
This lends support to the concept introduced above, 
that sporadic MSI-L cancers associated with MGMT 
methylation may represent a unique entity characterized by 
a common cluster of  molecular and pathological events, 
some of  which can be identified even at the earliest stages 
of  carcinogenesis.
meThylaTOR paThway
DNA methylation is an epigenetic means of  regulating 
gene transcription. Methylation of  DNA can occur at 
cytosine bases when cytosine and guanosine occur in 
a dinucleotide pair, i.e. CpG. DNA methylation occurs 
throughout the genome, and many interspersed repetitive 
DNA elements, such as Alu, LINE and SINE families 
of  sequences, are methylated during health. In contrast, 
CpG islands found within the promoter sequence of  
many genes are usually unmethylated[52]. Specific promoter 
sequence methylation can occur physiologically to silence 
particular genes, such as in X-chromosome inactivation, 
while disordered promoter methylation may also occur 
pathologically as an important event in carcinogenesis[53]. 
In CRC there is often both global hypomethylation of  
the genome, largely in the repeat DNA sequences and 
simultaneous hypermethylation of  the promoter regions 
of  strategic genes[54]. Promoter sequence methylation 
Table 1  Characteristics of different CRC pathways
Predominant 
pathway
MSI/CIMP 
status
Site of 
cancer
Prognosis CIN Germline 
MMR mutation
Somatic BRAF 
mutation
MLH1 
methylation
MGMT 
methylation
Immediate 
precursor
Mutator MSI-H/CIMP- Proximal Better No Yes No No No Advanced adenoma
Methylator/Mutator MSI-H/CIMP+ Proximal Better No No Yes Yes No Serrated polyp
Methylator Non-MSI-H/CIMP+ Proximal Worse No No Yes No No Serrated polyp
“Alternate” methylator MSI-L/CIMP+ Distal Unclear No No No (K-ras) No Yes Serrated polyp
Suppressor Non-MSI-H/CIMP- Distal Standard Yes No No No No Advanced adenoma
MSI: Microsatellite instability; CIMP: CpG island methylator phenotype.
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inter rupts gene express ion by direct ly inhibit ing 
transcription factor binding, as well as influencing histone 
acetylation, and thus accessibility of  the gene to the 
necessary transcriptional machinery[55]. In carcinogenesis, 
epigenetic silencing of  gene transcription by CpG island 
methylation is biologically equivalent to acquiring an 
inactivating mutation. Thus, methylation can occur as the 
first, second or both hits, to silence important tumour 
suppressor genes.
Severa l genes are associated with CpG is land 
methylation in CRC (Type C genes, MLH1, p16), whilst 
other genes are predominantly methylated in normal 
colorectal mucosa, and only occasionally methylated in 
cancer (Type A)[53,56]. In normal mucosa the type A genes 
(MINT6, MINT24, MINT32, ER) are associated with 
increasing age[53,56]. The mechanism driving these epigenetic 
events is uncertain. It is possible that environmental and 
luminal factors contribute to colorectal DNA methylation. 
The interface between diet, genetic predisposition, 
luminal environment and colorectal methylation will be an 
important area for future colorectal epigenetic research[53]. 
Currently there are two main methylation marker 
panels. These panels are used in an analogous fashion 
to the NIH MSI panel to classify cancers as CpG Island 
Methylator Phenotype positive or negative (CIMP + or -). 
Depending on the markers used, 24%-51% of  all CRCs 
are CIMP+[56-59]. The first panel that was proposed, and 
the one that many studies have used, includes analysis of  
the promoter regions of  the genes MLH1, p16, MINT 
1, 2, and 3 [56,60]. CIMP+ cancers often occur in older 
women, with a predominance of  proximal colonic lesions. 
Sporadic MSI-H cancers share a similar phenotype, but 
CIMP+ characteristics remain even in the setting of  non-
MSI-H tumours[61], and although MSI-H cancers are 
associated with a good clinical outcome, CIMP+/non-
MSI-H tumours generally have a poorer prognosis[62]. 
CIMP+ cancers also share common molecular events. 
Most CIMP+ cancers contain a BRAF mutation, but those 
that don’t have a BRAF mutation often have a mutation in 
K-ras[52,63]. BRAF and K-ras mutations occur in a mutually 
exclusive fashion, suggesting that a pathway common to 
both is critical to the development of  these cancers. The 
RAS-RAF-MEK-ERK signaling pathway is important 
in apoptosis and in particular anoikis, the process of  
apoptosis following loss of  the epithelial connection to 
the basement membrane[64]. Failure of  anoikis is important 
in the development of  hyperplastic polyps and serrated 
adenomas, which are the postulated precursors of  
CIMP+ CRCs[65]. BRAF and K-ras mutations interrupt 
the RAS-RAF-MEK-ERK signaling pathway at different 
levels, impairing normal anoikis. As alluded to above, the 
hypothesis of  the serrated neoplasia pathway, in which 
serrated polyps (admixed polyps, hyperplastic polyps, and 
serrated adenomas) are precursors to CIMP+ CRCs, is 
further supported by the recent finding that 78% of  sessile 
serrated adenomas exhibit BRAF mutation[66]. 
The main limitation of  the originally proposed 
CIMP panel outlined above is its inability to reliably 
classify cancers into well defined subsets[67]. Therefore, 
an alternative panel of  markers (CACNA1G, IGF2, 
NEUROG1, RUNX3, SOCS1) has been proposed[52]. 
In this new panel, methylation is defined quantitatively 
and cancers are defined according to the percentage 
methylation ratio (PMR), with CIMP+ CRCs having a 
PMR of  > 10 at 3 or more of  the 5 sites[52]. Using this new 
panel, CRCs distribute bimodally into CIMP+ and CIMP- 
cases, with an even closer correlation between CIMP+ and 
BRAF mutation.
CIMP+ CRCs are associated with methylation and 
frequent silencing of  MLH1 with resultant high levels 
of  MSI. Thus, there is a clear relationship between the 
sporadic mutator (MSI) and methylator (CIMP) pathways. 
However, CIMP is at least as common in non-MSI-H 
cancers[52], and although these lesions are also associated 
with BRAF mutation, the epigenetic silencing of  MLH1 
does not occur. These CRCs are associated with a worse 
prognosis[64,68]. The additional events regulating both 
prognosis and MLH1 methylation and thus MSI status 
are unclear. As discussed above, there is an association 
between MGMT methylation and K-ras mutation in a 
subset of  non-MSI-H/CIMP+ cancers. It is possible 
that mutation of  BRAF with or without methylation 
of  MLH1 may define one methylator pathway, whilst 
the development of  K-ras mutation and methylation of  
MGMT, could characterize an “alternate methylator” 
subtype, giving rise to MSI-L cancers[61]. 
CONClUsION
The discussion above has outlined three pathways to 
CRC (Table 1). Firstly, there is the CIN pathway, or the 
suppressor pathway, characterized by stepwise mutation or 
deletion of  K-ras, APC, SMAD2, SMAD4 and DCC, and 
p53. The Wnt-signaling pathway is likely to be important 
in many of  these cancers, and there is a developing role 
of  APC as a regulator of  CIN. Fortunately, the vast 
majority of  cancers in this pathway, never fully realize 
their neoplastic potential. This pathway begins with the 
dysplastic ACF, passes through simple and then advanced 
adenomatous stages, and, in a minority, produces an MSS 
cancer. The second pathway is the mutator pathway which, 
in its purest form (HNPCC), results from a germline 
mutation in a mismatch repair gene. The majority of  
MSI-H cancers, however, occur sporadically following 
the epigenetic silencing of  MLH1. Cancers from this 
pathway, which is really a combination of  the mutator 
and methylator pathways, may begin as hyperplastic 
ACF, becoming right sided hyperplastic polyps, serrated 
adenomas, and ultimately MSI-H, proximal colonic cancers. 
BRAF mutation and associated failure of  anoikis may be 
important at least in the early stages of  this pathway. The 
final pathway, the methylator pathway, is usually associated 
with BRAF mutation with or without epigenetic silencing 
of  MLH1 to contribute to MSI-H (mutator/methylator 
pathway, above) or non-MSI-H CRC, respectively. There 
may be an alternate methylator pathway, without BRAF 
mutation, but rather with the acquisition or maintenance 
of  K-ras mutation, and methylation of  MGMT. The 
precursor lesions for these ultimately MSI-L cancers may 
also be serrated polyps, but this is an area requiring further 
research.
Many challenges remain in the understanding of  
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colorectal carcinogenesis, including discovery of  the 
mechanisms driving CIN and DNA methylation. In 
addition, further study of  the molecular events found in 
apparently normal mucosa would be worthwhile. Normal 
appearing, non-resection mucosa escapes the surgeon’s 
knife but should not escape the attention of  colorectal 
researchers as this tissue may provide insight into the key 
stimuli that initiate and then influence cancer pathways. 
A better understanding of  the sequence of  events from 
normal to early and advanced pre-invasive lesions will 
have clear benefit when recommending surveillance 
strategies for patients, as well as in identifying potential 
targets for screening and therapy. Ultimately, knowing 
the environmental and luminal factors that may initiate 
or exacerbate these pathways will be critical in the 
development of  preventative strategies.
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